Dr Naeem Khan PhD

Institute of Immunology and Immunotherapy
Senior Research Fellow

Contact details

Telephone
+44 (0)121 414 6785
Email
n.khan.2@bham.ac.uk
View my research portal
Address
Clinical Immunology Service
Institute of Immunology and Immunotherapy
Medical School (East Wing)
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Dr Khan is a senior research scientist based in the Institute of Immunology and Immunotherapy. He is involved in flow cytometric analysis of leukemia patients enrolled on national acute myeloid leukemia (AML) trials.

Qualifications

  • Fellow of the Higher Education Academy, University of Liverpool
  • PhD in Cancer Studies 2002, University of Birmingham
  • MSc in Immunology and Immunogenetics, University of Manchester
  • BSc (Hons) in Biochemistry, University of Manchester

Biography

Current research is aimed at advancing our understanding of myeloid cell biology and translating this to improve treatment outcomes for myeloid leukemia patients. Presently, the senior scientist on the AML trials group applying a broad range of modern research skills to dissect differences in the many primitive cell populations in bone marrow from leukaemic patients. Also engaged in collaborations with national and international leukemia clinical research groups.

Teaching

Postgraduate supervision

Supervising BMedSc student projects:

  • Developing novel flow cytometry assays for predicting chemosensitivity in acute myeloid leukemia patients

Research

  • Acute myeloid leukemia and myelodysplastic /myeloproliferative disorders
  • Developing improved immunophenotyping panels for blood cancers
  • Deep immunophenotyping of immune cells using CyTOF mass cytometry in health and disease
  • Hi-dimensional cytometry data analysis using novel clustering algorithms

Other activities

  • Peer reviewer for a range of journals and funding bodies

Publications

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK, Freeman SD. (2017) Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia. 31(5): 1059-1068 doi: 10.1038/leu.2016.309.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS and Freeman SD (2016) Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia. PLoS One 11(9):e0163291

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Grech A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK and Freeman S (2015) Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials. ASH abstract

Halawi M, Khan N and Blake N (2015) Identification of novel CD8+ T cell epitopes in human herpesvirus 6B U11 and U90. Immun Inflamm Dis 3(2):118-31

Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, Grech A, Vyas P, Grimwade D, Russell NH, Burnett AK and Hills RK (2015) An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older AML patients: blood frequency of CD34+CD38low blasts. Br J Haematol 170(1):80-84

Bradbury C, Houlton A, Akiki S, Gregg R, Rindl M, Khan J, Ward J, Khan N, Griffiths M, Nagra S, Hills R, Burnett A, Russell N, Vyas P, Grimwade D, Craddock C and Freeman SD (2015) Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia. Leukemia 29(4):988-91

Alejenef A, Pachnio A, Halawi M, Christmas SE, Moss PA and Khan N (2014) Cytomegalovirus drives Vd2neg gamma delta T cell inflation in many healthy virus carriers with increasing age. Clin Exp Immunol 176(3):418-28

Almehmadi M, Flanagan BF, Khan N, Alomar S and Christmas SE (2014) Increased numbers and functional activity of CD56+ T cells in healthy cytomegalovirus positive subjects. Immunology 142(2):258-68

View all publications in research portal